F-8
ISISPHARMACEUTICALS, INC.
CONSOLIDATEDSTATEMENTSOFCASHFLOWS
(In thousands)
Supplemental disclosures of cash flow information:
Interest paid ................................................................................................... $
6,000 $
5,770 $
4,804
Income taxes paid, net of refund received .................................................... $
2 $
2 $
2
Supplemental disclosures of non-cash investing and financing activities:
Amounts accrued for capital andpatent expenditures .................................. $
704 $
647 $
902
Capitalized costs and financing liability associatedwith leased facility ....... $
— $
— $
59,730
See accompanyingnotes.
